Lipocine To Present At The Raymond James Human Health Innovation Conference
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Raymond James Human Health Innovation Conference from June 21-23, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) announced its participation in the Raymond James Human Health Innovation Conference from June 21-23, 2021. The presentation is scheduled for June 21 at 12:40 PM ET. Interested parties can access the webcast here. The company focuses on metabolic and endocrine disorders, with key products including TLANDO, LPCN 1144, and others aimed at treating conditions such as hypogonadism and non-cirrhotic NASH.
Details
News Market Reaction – LPCN
The recorded move for LPCN in the trading session of this news was +1.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will be held virtually. Presentation details are below.
Raymond James Human Health Innovation Conference June 21-23
Presentation time: June 21, 2021 starting at 12:40 PM ET
Webcast link: https://kvgo.com/rj-health/lipocine-inc-june-2021
The webcast of this presentation will also be available on Lipocine's corporate website under "Events & Presentations" in the Investors section.
About Lipocine Inc.
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression. For more information, please visit www.lipocine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-raymond-james-human-health-innovation-conference-301313327.html
SOURCE Lipocine Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.